India’s Weight Loss Drug Market Shifts

A major shift is underway in India’s obesity and diabetes care, as semaglutide’s patent expiry is set to make weight-loss injections far more affordable.

The expiry of Novo Nordisk’s semaglutide patent in India on March 20, 2026, marks a turning point in obesity and diabetes care. From March 21, a wave of affordable generic versions is expected to enter the market, significantly reducing costs and expanding access to treatment (1^✔ ✔Trusted Source
Semaglutide Patent Expiry in India: ₹5000 Crore Pharma Business Opportunity

Go to source

).
The expiry of Novo Nordisk’s semaglutide patent in India on March 20, 2026, marked a turning point in obesity and diabetes care. From March 21, a wave of affordable generic versions was expected to enter the market, significantly reducing costs and expanding access to treatment.

Semaglutide is a GLP-1 receptor agonist—a class of drugs that helps regulate blood sugar and reduce appetite. Currently sold under brand names like Ozempic and Wegovy, it has become one of the most widely used therapies for both type 2 diabetes and weight management.

Semaglutide mimics the GLP-1 hormone, helping regulate blood sugar, slow digestion, and reduce appetite—making it effective for diabetes and weight loss. However, it is a prescription-only medicine meant for type 2 diabetes and clinically overweight or obese individuals, not for casual or cosmetic use (3^✔ ✔Trusted Source
How Does Semaglutide Work? Explained Simply

Go to source).

Will Cheaper Semaglutide Transform Access to Weight Loss Treatment?

The most immediate impact is financial. Monthly treatment costs, which previously ranged from ₹8,000 to ₹16,000 or more, are expected to fall to around ₹3,000–₹4,000, with further reductions likely as competition increases.

This sharp price drop is expected to bring treatment within the reach of India’s middle and upper-middle-class populations. At the same time, more than 50 pharmaceutical companies, including Sun Pharma, Dr. Reddy’s, Cipla, and Zydus, are preparing to launch generic versions.

Beyond just injections, a broader shift in care is emerging. Patients may now receive integrated support—diet plans, regular follow-ups, and access to specialized obesity clinics, indicating a move toward more structured and long-term weight management.

India’s growing burden of disease makes this shift significant. With over 100 million people living with type 2 diabetes and rising obesity rates, demand for such therapies is expected to surge.

India’s GLP-1 market is about to witness explosive growth, with demand for diabetes and weight-management therapies expected to multiply nearly fivefold by 2030.

Indian pharmaceutical companies are moving quickly to capture this opportunity. Sun Pharma has already secured DCGI approval for semaglutide for chronic weight management and is preparing for rapid rollout, signaling intense competition in the coming months.

Is This a Safe Solution or a Risky Shortcut?

However, wider access also brings new challenges.

While the benefits are clear, concerns are growing around safety and misuse. Common side effects include:

• Nausea
• Vomiting
• stomach discomfort
• constipation

More serious risks, though less common, include:

• pancreatitis
• gallbladder issues
• kidney complications
• severe gastrointestinal conditions

A growing trend is the off-label use of semaglutide for cosmetic weight loss. Research analyzing thousands of patients has linked such use to complications like gastroparesis (delayed stomach emptying), bowel obstruction, and pancreatitis.

Surveys also show rising demand driven by aesthetic goals rather than medical need, highlighting a gap between clinical use and real-world behavior.

Can India Balance Affordability With Safe Use?

As access expands, the focus now shifts to regulation and responsible use.

The World Health Organization has emphasized that GLP-1 drugs should be used as part of a comprehensive care plan, including diet, physical activity, and medical supervision—not as standalone solutions (2^✔ ✔Trusted Source
WHO issues global guideline on the use of GLP-1 medicines in treating obesity

Go to source).

“Medication alone won’t solve this global health crisis,” the WHO notes, stressing the need for long-term, structured care.

As affordability improves, new risks may emerge:

• self-medication
• overuse for quick weight loss
• counterfeit or low-quality products
• uneven regulatory oversight

At the same time, not all drugs in this category will become cheaper. Newer therapies like tirzepatide remain under patent protection, limiting similar price drops.

This moment marks a major shift in India’s healthcare landscape. Cheaper semaglutide has the potential to transform obesity and diabetes care at scale.

But the real challenge lies ahead—ensuring that increased access does not come at the cost of safety, awareness, and responsible medical use.

References:

1. Semaglutide Patent Expiry in India: ₹5000 Crore Pharma Business Opportunity – (https://www.niir.org/blog/semaglutide-patent-expiry-india/)
2. WHO issues global guideline on the use of GLP-1 medicines in treating obesity – (https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity)
3. How Does Semaglutide Work? Explained Simply – (https://semaglutidemedics.org/blog/how-does-semaglutide-work-explained/)

Source-Medindia